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Objective: The aim of the study was to characterise the protein complement of synovial ﬂuid (SF) in
health and osteoarthritis (OA) using liquid chromatography mass spectrometry (LC-MS/MS) following
peptide-based depletion of high abundance proteins.
Design: SF was used from nine normal and nine OA Thoroughbred horses. Samples were analysed with
LC-MS/MS using a NanoAcquity™ LC coupled to an LTQ Orbitrap Velos. In order to enrich the lower-
abundance protein fractions protein equalisation was ﬁrst undertaken using ProteoMiner™. Pro-
genesis-QI™ LC-MS software was used for label-free quantiﬁcation. In addition immunohistochemistry,
western blotting and mRNA expression analysis was undertaken on selected joint tissues.
Results: The number of protein identiﬁcations was increased by 33% in the ProteoMiner™ treated SF
compared to undepleted SF. A total of 764 proteins (462 with2 signiﬁcant peptides) were identiﬁed in
SF. A subset of 10 proteins were identiﬁed which were differentially expressed in OA SF. S100-A10, a
calcium binding protein was upregulated in OA and validated with western blotting and immunohis-
tochemistry. Several new OA speciﬁc peptide fragments (neopeptides) were identiﬁed.
Conclusion: The protein equalisation method compressed the dynamic range of the synovial proteins
identifying the most comprehensive SF proteome to date. A number of proteins were identiﬁed for the
ﬁrst time in SF which may be involved in the pathogenesis of OA. We identiﬁed a distinct set of proteins
and neopeptides that may act as potential biomarkers to distinguish between normal and OA joints.
© 2015 The Authors. Published by Elsevier Ltd and Osteoarthritis Research Society International. This is
an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Introduction
Osteoarthritis (OA) is a joint disease characterised by alterations
in the chondrocytes and loss of cartilage extracellular matrix
(ECM)1, leading to biomechanical failure of articular cartilage. The
molecular mechanisms involved in OA are not fully understood,
with few currently validated markers for disease diagnosis and
progression. Delayed diagnosis precludes preventive or timely
therapeutic interventions. These limitations could be surmounted
by enhanced knowledge of articular tissue metabolism and
homoeostasis.o: M.J. Peffers, Comparative
ronic Disease, University of
l, CH64 7TE, UK.
s), benmcd@liverpool.ac.uk
christopher.m.riggs@hjkc.org.
r Ltd and Osteoarthritis Research SSynovial ﬂuid (SF) is located in joint cavities and comprises a
serum ﬁltrate with additional contributions from surrounding tis-
sues. As it is in direct contact with the OA-affected tissues it has
been implicated as a contributor to OA pathophysiology. It also
represents a potential source of disease-speciﬁc proteins that could
both aid in the understanding of the pathogenesis of joint disease
and act as disease biomarkers.
To date a number of mass spectrometry (MS)-based proteomic
studies have been performed on both normal2 and diseased3e5 SF,
with a variety of MS techniques4e6. In common with serum, SF
contains many of high-abundant proteins (HAPs) with concentra-
tions exceeding other proteins by estimated ten-orders of magni-
tude. Removal of HAPs aids in the detection of the lower abundance
proteins which may be important in both OA pathogenesis and
biomarker discovery. Immunoafﬁnity depletion has been used to
remove these HAPs5,7,8; however large proteins, such as albumin,
frequently act as carriers for other proteins which may themselves
be signiﬁcant9. Another method of compressing the dynamic range
of protein but also enabling the entire proteome to bemaintained isociety International. This is an open access article under the CC BY license (http://
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hexapeptide ligand libraries immobilized on a solid phase matrix
and has been used in serum proteomic studies11. This is the ﬁrst
time this approach has been used in SF proteomics.
The horse provides an accepted model for the study of ar-
thropathies12,13 as it suffers similar clinical joint diseases to those
seen in man14e16.
In this study we designed an innovative workﬂow to study
normal and OA SF proteomic signatures. We used a well-
documented cohort of skeletally mature horses, peptide-based
depletion dynamic compression, LC-MS/MS with a high mass res-
olution instrument and label-free quantiﬁcation. Additionally we
identiﬁed several novel disease-associated peptide fragments
(neopeptides).
Methods
All chemicals were supplied by Sigma unless otherwise stated.
SF sampling and procurement
SF, cartilage, subchondral bone and synovial membrane from
the metacarpophalangeal joints of nine normal mean ± standard
deviation (5.1 ± 0.5 years) and nine OA (6.5 ± 0.4 years) castrated
male Thoroughbred horses at post-mortem. Samples were
collected under the regulations of the Hong Kong Jockey Club with
owner consent and stored at 80C. OA diagnosis was based on
macroscopic17, histological (modiﬁed Mankin)18 and synovitis
scoring19 undertaken on joint tissues.
SF preparation and protein depletion with ProteoMiner™
SF (1 ml) was treated with 1 mg/mL of hyaluronidase5. The su-
pernatant was centrifuged through a 0.22 mm cellulose acetate
membrane (Costar Spin-X, Corning, Tokyo, Japan) tube ﬁlter
(5000 g/15 min) to remove insoluble material. Protein concen-
trations of SF were determined by Bradford assay (Thermo Scien-
tiﬁc, Rockford, IL, USA).
For peptide-based depletion, 5 mg SF was bound to its own spin
column containing ProteoMiner™ Small Capacity beads (Bio-Rad
Laboratories, Hemel Hempstead, UK) with on-bead trypsin
digestion.
1-D SDS PAGE
Following ProteoMiner™ treatment of one sample the eluate
along with the ﬂow-through (containing depleted proteins) and a
sample of native SF were analysed by one dimensional sodium
dodecyl sulphate polyacrylamide gel electrophoresis (1D-SDS-
PAGE)20 to assess quantitative/qualitative differences in protein
proﬁles.
In-solution tryptic digestion and MS
Following in-situ trypsin digestion on ProteoMiner™ beads
samples were treated with 1% (w/v) RapiGest (Waters, Manchester,
UK) for 10 min at 80C in 25 mM ammonium bicarbonate. To
determine the effect of protein equalization of SF, equivalent pro-
tein from one sample of SF (undepleted sample) was digested by in-
solution tryptic digestion21. LC-MS/MS analysis was performed on
2 ml aliquots of tryptic peptides equivalent to 1:10 dilution of the
total digest using a 2 h gradient on a NanoAcquity™ ultra-
performance LC (Waters, Manchester, UK) on line to an LTQ-
Orbitrap-Velos (Thermo-Fisher Scientiﬁc, Hemel Hempstead, UK)
as previously described22.Database search and protein identiﬁcation
Raw spectra were converted to mascot generated ﬁles (mgf)
(Proteome Discoverer software (Thermo, Hemel Hempstead, UK)).
The resulting mgf ﬁles were searched against the Equus caballus
database; Ensembl database for horse (Equus caballus; Equ-
Cab2.56.pep, (ftp://ftp.ensembl.org/pub/current_fasta/equus_
caballus/pep/)) using an in-house Mascot server (Version 2.3.01)
(Matrix Science, London, UK). Search parameters used were:
enzyme; trypsin, peptide mass tolerances, 10 ppm; fragment mass
tolerance, 0.6 Da; 1þ, 2þ and 3þ ions; missed cleavages, 1; in-
strument type, ESI-TRAP. Modiﬁcations included were: ﬁxed car-
bamidomethyl cysteine and variable; oxidation of methionine,
lysine, proline.
Label-free quantiﬁcation
The Thermo raw ﬁles of the acquired spectra from in-solution
tryptic digests were analysed by the Progenesis™ LC-MS software
(Version 4, Nonlinear Dynamics)21. The top three spectra for each
feature was exported from Progenesis-QI™ and utilized for peptide
identiﬁcation against the E. caballus database. Search parameters
used were: 10 ppm peptide mass tolerance and 0.6-Da fragment
mass tolerance; one missed cleavage allowed; ﬁxed modiﬁcation,
carbamidomethylation; variable modiﬁcations, methionine oxida-
tion, proline oxidation, and lysine oxidation. To maximize the
number of quantiﬁable proteins but simultaneously use an
acceptable false discovery rate (FDR), the peptide matches above an
identity threshold were adjusted to give an FDR of 1% before the
protein identiﬁcations being re-imported into Progenesis-QI™.
Mascot determined peptides with ion scores of 20 and above, and
only proteins with at least one unique peptide ranked as the top
candidate were considered and analysed with only unique peptides
being included. Statistical analysis was performed using trans-
formed normalized abundances for one-way analysis of variance
(ANOVA). All peptides (with Mascot score >23 and P < 0.05) of an
identiﬁed protein were included, and the protein P-value (one-way
analysis of variance) was then performed on the sum of the
normalized abundances for all runs. Adjusted ANOVA values of
P < 0.05 and additionally regulation of >2-fold or <0.5-fold were
regarded as signiﬁcant.
Neopeptide identiﬁcation
For neopeptide determination, MS data from the in-solution
tryptic digests of normal and OA SF were analysed22. Filters for
inclusion of neopeptides were as previously described22. Patterns
of fragmentation were determined for aggrecan, biglycan, decorin,
ﬁbromodulin, and cartilage oligomeric matrix protein (COMP).
Protein network analysis
Gene ontology (GO) was undertaken on the complete list of
proteins identiﬁed in SF using the Panther Classiﬁcation System
version 9.0 (www.pantherdb.org)23 and Database for Annotation,
Visualization and Integrated Discovery (DAVID) version 6.724.
Western blotting validation of S100A10 abundance
All validation studies were undertaken with an independent
cohort but from the same population and with similar age ranges
andmacroscopic, Mankin's and synovitis scores. In order to validate
the increased S100A10 abundance in OA SF, 50 mg total protein from
normal and OA donors was used in western blot analysis25 using
rabbit polyclonal to S100A10 (1:100 dilution, ABIN1386030,
Fig. 1. Coomassie Brilliant Blue stain of 1D SDS e PAGE gel of depleted and undepleted
synovial ﬂuid. All SF was pretreated with hyaluronidase as described in the methods.
The lanes represent depleted (20 mg loading); 5 mg SF was loaded onto the Proteo-
Miner™ column and ﬁnal eluted fraction represents depleted, ﬂow through prior to
elution; 60 mg load and undepleted; 60 mg native SF.
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conjugated goat anti-rabbit secondary antibody at 1:2000 and
Western Lightning™ and Western Lightning Plus Chem-
iluminescence reagents (Perkin Elmer, Beaconsﬁeld, USA). Blots
were imaged using VisionWorksLS image acquisition software
package and band densities were analysed using ImageJ 1.42.
Immunohistochemistry of S100A10
Immunohistochemistry of cartilage and synovial membrane
samples for S100A10 was undertaken26 using the primary antibody
anti-S100A10 at 1:100 in blocking solution. The secondary antibody
was a polyclonal anti-rabbit (Z0196, Dako UK Ltd., Ely, UK) at 1:100.
No staining was observed in control experiments carried out with
omission of the primary antibody and substitution with non-
immune rabbit IgG (Abcam, Cambridge, UK). Digital image anal-
ysis was undertaken using ImageJ using the ‘threshold-color’
method27.
RNA extraction and gene expression analysis
Cartilage, subchondral bone and synovial membrane from the
metacarpophalangeal joint of selected normal (n ¼ 8) and OA
(n¼ 3) donors was collected into RNAlater and RNA extracted12. M-
MLV reverse transcriptase and random hexamer oligonucleotides
(both Promega, Southampton, UK) were used to synthesize cDNA
from 1 mg RNA in a 25 ml reaction. PCR was performed on 1 ml 10
diluted cDNA, employing a ﬁnal concentration of 300 nM of each
primer in 20 ml reaction volumes on an ABI 7700 Sequence Detector
using PrimerDesign 2X PrecisionTM SYBRGreenMastermix (Primer
Design, Southampton, UK) using exon-spanning primers (Primer
Design, Southampton, UK). Relative expression levels were nor-
malised to GAPDH and calculated using the 2^ DCt method28,29.
Primers for equine GAPDH have been previously described28;
S100A10 forward; GGGCTCACCATCGCATG, reverse; GTGGGAG-
GAATTGCTCAATG and CD109 forward; AAGGAGACAAGCGGTGA-
GAA, reverse; CGACAGACGAGTGACAACAG. RT-PCR analysis data
was log10 transformed to ensure normal distribution and analysed
using Student's t test.
Results
Macroscopic and histological assessment
Macroscopic scoring of samples from normal donors was 0 and
OA donors were 2.3 ± 0.1SD. Normal donors had a Mankin's score
0.88 ± 0.4SD and OA donors 13.5 ± 1.4SD. Synovial membrane score
from normal donors had a synovitis score of 1.2 ± 0.2SD and OA
1.7 ± 0.2SD.
Protein depletion of SF
We used a peptide-based afﬁnity method, to increase identiﬁ-
cation of low abundance proteins. To investigate the efﬁciency of
this method we resolved non-depleted and depleted samples on a
1-D SDS PAGE gel to compare protein proﬁles. The peptide-based
afﬁnity method reduced the amount of albumin evident by a
marked reduction in the 60 kDa albumin band (Fig. 1).
We then compared SF trypsin digests, with and without
depletion, using LC-MS/MS and identiﬁed 204 proteins and 318
proteins (150 and 243 with signiﬁcant Mascot score and 2
peptides) for native and ProteoMiner™ SF respectively; a 38% in-
crease with ProteoMiner™. A list of proteins identiﬁed is in
Additional File 1.Identiﬁcation of proteins following ProteoMiner™ in normal and OA
SF
A total of 764 proteins were identiﬁed in combined samples
from SF; 462 with a signiﬁcant Mascot score of >20 and 2 pep-
tides. A global FDR of less than 3% was calculated by running a
parallel search in a decoy database. Additional File 2 provides
detailed information on the identiﬁcation of each protein and
corresponding Mascot scores.
For SF the total dataset with a signiﬁcant Mascot score were
either transformed to a non-redundant gene identiﬁer list of the
respective human homologues for DAVID analysis or input directly
into Panther. Panther classiﬁed the proteins as cellular components
(28%), cell organelles (26%), extracellular region (24%), ECM (15%)
and macromolecular complex (7%).
Figure 2 demonstrates the GO biological processes and molec-
ular functions identiﬁed. Additional File 3 details protein class and
cellular components identiﬁed. DAVID identiﬁed four signiﬁcant
Kegg pathways from the data set; complement and coagulation
cascade, systemic lupus erythematosus, prion diseases and antigen
processing and presentation (Bonferroni-adjusted P-values of
1.72E-23, 2.58E-14, 0.001, 0.04 respectively). Additional File 4
contains all results.
Label-free relative quantiﬁcation
In order to compare relative protein levels between normal and
OA SF, samples were processed for LC-MS/MS and quantitative
analysis undertaken with Progenesis-QI™. Principal component
analysis of differentially expressed (DE) proteins with a greater
than two-fold change in expression and P < 0.05 revealed that the
proteins clustered according to OA status of the donor (principal
Fig. 2. GO of SF using Panther. All proteins identiﬁed in SF were input into Panther protein classiﬁcation software in order to determine the GO terms for (a) biological processes and
(b) molecular function. Pie charts are representative of the percentage of proteins within each classiﬁcation.
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tween normal and OAwith2 peptides. Six proteins were higher in
OA SF and four proteins were lower in OA SF (Table I).Identiﬁcation of ECM fragmentation patterns
A catalogue of OA related neopeptides in SF were identiﬁed for
aggrecan, biglycan, COMP, decorin, ﬁbromodulin, collagen alpha-
1(I) and collagen alpha-3(VI) (Table II).Western blot validation of S100A10
We attempted to verify the results for the two proteins
increased in SF with signiﬁcant q-values; S100A10 and CD109.
Unfortunately although antibodies were sourced with predicted
reactivity against equine CD109, they did not work. We validated
results for S100A10 using immunoblotting which conﬁrmed that
S100A10 appeared more abundant in OA SF (Fig. 3).Characterization of S100A10 in normal and OA cartilage and
synovium
Immunohistochemistry analysis of cartilage and synovium from
normal and OA horses, using anti-S100A10, was undertaken to
determine the strength of expression and its tissue distribution.
Immunohistochemistry revealed reduced expression of S100A10 in
a homogenous and diffuse pattern in OA synovium compared to
normal synovium (P ¼ 0.02; Student's t test) [Fig. 4(a) and (c)]. In
contrast there was an increase in expression of S100A10 in OA
compared to normal cartilage (P ¼ 0.005; Student's t test) [Fig. 4(b)
and (c)] demonstrated by increased diffuse staining in the
tangential and transitional cartilage layers.S100A10 and CD109 gene expression in joint tissues
To determine whether the difference in S100A10 and CD109 we
observed in OA SFwas due to local production or represented extra-
articular production we undertook gene expression analysis of
cartilage, subchondral bone and synovium from normal and OA
donors. There were signiﬁcant tissue and disease differences in the
relative gene expression of both CD109 and S100A10 (Fig. 5).
Table I
A number of differentially abundant proteins were identiﬁed by Progenesis™ LC-MS software between normal (A) and OA (B) SF using unique peptides only. All proteins with a
>2-fold change and P < 0.05 in normalised abundance are shown
Highest mean
condition
Accession Protein Role Peptide
count
Fold
change
ANOVA
OA NP_001157339.1 S100-A10* Calcium binding protein 2 2.2 0.000283
XP_001498093.2 CD109 antigen* TGF b co-receptor 9 2 0.000391
XP_001503419.1 Phospholipid transfer protein isoform 1 Lipid transfer protein 17 2.7 0.000981
XP_001916113.1 Complement component C8 gamma chain Constituent of the membrane attack
complex
6 3.1 0.011525
XP_001499636.3 Collagen alpha-1(I) chain Fibrillar collagen 22 2.8 0.045984
XP_001490837.3 Calsyntenin-1 Calcium binding protein 6 2.1 0.048534
Normal XP_001489891.1 Integral membrane protein 2B Processes amyloid A4 precursor protein 2 2.1 0.000676
XP_001490429.3 Mannan-binding lectin serine protease 2 Protease 3 2.2 0.006101
XP_001504425.1 Keratin, type II cytoskeletal 7 Blocks interferon-dependent interphase 8 2.2 0.011439
XP_001488573.1 Cyclin D binding myb-like transcription
factor 1 isoform 1
Transcriptional activator 2 6.2 0.024012
* In addition these proteins had a signiﬁcant false-discovery rate adjusted P < 0.05.
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We have performed a comprehensive proteomic analysis of
normal and OA SF identifying disease-related alterations to the
proteins in OA. LC-MS/MS with high mass resolution instruments
has enabled rapid advances in protein proﬁling of complex body
ﬂuids including SF2,4 which enables novel opportunities for gaining
disease insight. Using label-free quantiﬁcation, comparing age-
matched controls, we identiﬁed a number of DE proteins in OA SF.
In order to minimise the high inter-donor variability previously
reported30 we used post-mortem samples from a cohort of race-
horses which were housed and trained at a single location, were
age-matched (young, skeletally mature), of the same sex and we
had access to macroscopically and histological details of the carti-
lage, subchondral bone, synovium. In addition we had full knowl-
edge of their training and medical histories. This enabled us to
choose control donors that had no pathological changes to the
cartilage and limited synovium changes. In addition age-matching
removed any age-related changes.
We developed a peptide-based afﬁnity method (ProteoMiner™)
which has been demonstrated to have a high level of reproduc-
ibility and consistency in terms of the species and quantities of
proteins captured31. This method condenses the dynamic range of
protein concentrations, whilst retaining a large proportion of the
entire repertoire of proteins present in the initial sample,
increasing resolving power of proteome characterisation. More-
over, as wewere analysing equine SF there was a potential for poor-
performance using afﬁnity depletion methods based on human
antigens. Previous work had demonstrated their usefulness in
bovine serum studies32. It has been demonstrated that reliable
differential quantitative data can be obtained from samples sub-
mitted to protein equalization11,33. However it is important to
validate any ﬁndings with other methodologies. Whilst many
studies have undertaken selected reactionmonitoring (SRM) assays
to validate results the peptide-based afﬁnity method is now vali-
dated in many papers11. In one study 35 differentially expressed
proteins were identiﬁed and the top 17 validated with SRMs and all
agreed with the ProteoMiner™ data34. Furthermore a study has
demonstrated that the enrichment (of medium and low abundance
proteins) maintains quantitative information. The linearity of
response to the addition of increasing amounts of serum amyloid A
was demonstrated usingMS33. Thereforewe used other methods to
validate and investigate our ﬁndings further. To estimate the efﬁ-
ciency of this method in SF proteomics we resolved non-depleted
and depleted samples by 1D-SDS-PAGE. This conﬁrmed depletion
resulted in a more complex visual protein proﬁle together with a
reduction in some abundant bands. Furthermore we analysed non-depleted and depleted SF from the same donor using LC-MS/MS.
This demonstrated a signiﬁcant increase (38%) in the number of
proteins identiﬁed following depletion, agreeing with serum
comparative quantitative proteomics studies35. We identiﬁed 16 of
the 20 proteins identiﬁed in a previous immunodepletion study5 in
both depleted and undepleted samples. All except two of these had
a reduced protein identiﬁcation Mascot score and protein hit
number in the depleted compared to undepleted sample. The
change in Mascot generated protein hit number varied. For
example albumin was the number one hit in undepleted SF and
following treatment with ProteoMiner™ it became the sixth
highest hit, whereas transferrinwent from the second highest hit to
the one hundred and thirty sixth highest hit.
In this study, following ProteoMiner™ treatment, LC-MS/MS
with a high mass resolution mass spectrometer and the software
Progenesis-QI™ we report one of the largest number of proteins
identiﬁed in SF to date. This was despite the presence of HAP (ﬁve
out of 10 of the top protein hits; complement C3, C4, albumin,
apolipoprotein AI and B) in the results, similar to recent ﬁndings in
normal porcine SF2. This was in part due to Progenesis-QI™
quantiﬁcation algorithms that measures all detected peaks and
then identiﬁes them, which favours identiﬁcation of low abun-
dance peptides36. A recent publication found 575 proteins using an
Isobaric Tags for Relative and Absolute Quantiﬁcation (iTRAQ)
study37 but this was a comparative study between OA and rheu-
matoid arthritis (RA) SF. Another study employing multiple frac-
tionation strategies following immunodepletion identiﬁed 677
proteins in OA SF8.
The diversity of proteins identiﬁed in SF included collagenous
and non-collagenous ECM proteins, proteases, signalling and im-
mune response proteins. Our data was in agreement with other
recent SF proteomics studies3,5,8,37 conﬁrming the validity of our
experimental workﬂow. Functional distribution of proteins by
Panther highlights the breadth of proteins, dominated by intra-
cellular and cell membrane proteins along with plasma proteins in
SF. Functional annotation clustering using DAVID identiﬁed a
number of Kegg pathways enriched. These included complement
and coagulation cascade, which can be accounted for by the pres-
ence of a number of complement proteins, whilst systemic lupus
erythematosus is represented by a number of complement proteins
in addition to proteases such as cathepsin and cell surface antigens
in SF.
We identiﬁed a number of DE proteins in OA. Of these the
calcium-binding protein S100A10 (increased in OA SF) plus integral
membrane protein 2B and cyclin D binding myb-like transcription
factor 1 isoform 1 (reduced in OA SF) were identiﬁed for the ﬁrst
time. In our label-free quantiﬁcationwewere stringent in the ﬁlters
Table II
Neopeptides identiﬁed in OA SF. Neopeptides shownwere identiﬁed byMascot with a signiﬁcant score in2 SF but no normal donors together with aminimum ion score of 20
Amino acids shown in red correspond to the end of the neopeptide corresponding to a potential cleavage site. Amino acids before and after represent those preceding the
peptide sequence and following the peptide sequence in the protein
Protein Amino 
acid 
before
PepƟde Sequence Amino 
acid 
aŌer
Aggrecan T TAPEVPGQPR L
Y PIHLPR E
Biglycan N CIEMGGNPL# E
N GISLFNNPVP° Y
P PNLPS^ S
V QPATFR C
Collagen alpha 1 (I) chain R GVPGPPGAVG P
R LLLLLAATALLTHGQEE G
R LLLLLAATALLTHGQEEGQEEGQ E
G APGPSGAR G
G PAGPTGAR G
G EAGPQGAR G
P GADGQPGAK G
P QGPSGPPGPK G
Q AGVMGFPGPK G
S PGENGAPGQMGPR G
T AGLPGMK G
Collagen alpha 3 (VI) chain K RNGIMAFAIG N
K QPSLETAMSFV& A
E DAQEASMALTQR G
G SGGAVGVPGER G
G ETGDLGPMGLPGSDGVSGSPGEPGR D
L DGISQPAQELK R
COMP D ACGMQPAR* T
L AQCAPGSCFPGVACTQTASGARCGP*°# C
M NSDPGLAVGYTA° F
N DDQKDTDQDGRGD* A
R VRCINTSPGFRCEACPPGYSGPTHEGVGM* A
W AGNGL* L
N ALWHTGDTASQVR# L
V MECDACGMQPARTPR V
Decorin Q MIVVELGTNPLK*# S
D GDFKNLK N
K LIKVPGGLA D
N GAFQGMK K
P GAFTPLVK L
M PADAPLC* L
Fibromodulin G LCSLSR A 
R SLRELHLDH N 
* denotes found in previous interleukin-1 cartilage explant study.
y denotes found in previous a disintegrin with thrombospondin motifs (ADAMTS4) study50.
z denotes found in previous matrix metalloproteinase 3 (MMP3) study50.
x denotes previously identiﬁed in matrix-assisted laser desorption ionisation study13.
k denotes previously identiﬁed in equine tendon study22.
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peptides were used for quantiﬁcation. Additionally, we only tar-
geted proteins for further study if differences had an FDR<0.05. This
was undertaken in order to give the most robust results possible.
Other SF studies have used 2D-DIGE3 or spectral counting5,7,8 to
quantify, and the different proteomic workﬂows will account for
differences evident between different studies.
Two proteins; CD109 and S100A10 were increased in OA SF with
signiﬁcant FDRs. CD109 is a transforming growth factor-b (TGF-b)
co-receptor, released from the chondrocyte cell surface which in-
hibits TGF-b signalling by promoting TGF-b receptor internalisation
and degradation38. CD109 has been detected in the peripheralcirculation and SF as a component of CD146-positive lymphocytes
in patients with numerousmusculoskeletal diseases39. Previously it
has also been identiﬁed in conditioned media of human articular
chondrocytes40, bovine cartilage explants treated with interleukin
1b (IL1-b)41, and human OA cell lysates42. We attempted to un-
dertake western blot validation and IHC in order to verify our MS
results and localise CD109 but were unable to ﬁnd a compatible
antibody. Gene expression analysis identiﬁed that CD109 was
expressed at the greatest level in synovium, followed by sub-
chondral bone and cartilage. Furthermore there was a reduction in
gene expression in OA synovium. Normal cartilage function is
dependent on a narrow scale of bioactive TGF-b, with aberrations
Fig. 3. Increased abundance of S100A10 in OA SF. Representative image of western blot
analyses of S100A10 (molecular weight 50 kD) in SF from ﬁve OA and three normal
donors demonstrates an increase in S100A10 in OA. The blots are representative of
eight OA and nine normal samples. Histogram represents mean pixel intensity of OA
and normal S100A10 protein bands mean 95%CI, **P ¼ 0.004 (Student's t test). Units
are arbitrary.
Fig. 4. Localization of S100A10 in joint tissues from normal and OA horses. Cartilage with u
probed with anti-S100A10 antibodies. Quantitative image analysis was undertaken using th
colour are selected for measurement; hence the y-axis in histograms (c) and (d) represents ‘a
representative OA donor (inset) compared with a sample of a normal donor. (b) Cartilage wit
normal donor. Histogram represents mean area for (c) synovial membrane for normal (n ¼
(n ¼ 3) mean 95%CI together with statistical signiﬁcance of results (Student's t test).
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resulting in abnormal cartilage function. As CD109 is an important
factor in regulating TGF-b signalling, alterations in CD109 within
the SF and synoviummay play a role in OA pathogenesis. It could be
that matrix degradation products or CD109 protein itself released
from damaged cartilage in OA and the former of which lead to
synovial inﬂammation may result in reduced CD109 expression in
an attempt to promote TGF-b signalling. Further work is required to
conﬁrm this hypothesis.
We identiﬁed S100A10 in SF for the ﬁrst time, although
increased expression of S100A10 protein has been identiﬁed in OA
and RA synovial ﬁbroblasts43. The calcium binding protein
S100A10, a member of the S100 family retains both intracellular
and extracellular functions; including cytokine-like activities44.
Several members of the S100 family have been identiﬁed in human
articular cartilage, and their expression is upregulated in both OA
and RA (reviewed by Yammani45). Other members of the S100
family have been demonstrated in OA6,8 and RA SF6. S100s have
been indicated as potential biomarkers of other arthopathies46.
Interestingly it has been established that some S100members elicit
a catabolic signalling pathway via receptors for advanced glycation
end products leading to increased production of matrix-degrading
enzymes; matrix metalloproteinases (MMPs) and a disintegrin and
metalloproteinase with thrombospondin motifs (ADAMTSs),
resulting in cartilage degradation and the development of
arthritis45. S100A10 has been isolated in a complex with Annexin IInderlying subchondral bone and synovium obtained from normal and OA horses were
e ‘Threshold’ method in ImageJ. This ensures that only areas stained with a designated
rea’. All images were captured at 20magniﬁcation. (a) Synovial membrane sample of
h underlying subchondral bone from a representative OA donor (inset) compared with a
3) and OA (n ¼ 2) and (d) cartilage with underlying bone for normal (n ¼ 4) and OA
Fig. 5. Gene expression at tissue and disease level of CD109 and S100A10. Cartilage, subchondral bone and synovium mRNA levels of (a) CD109, and (b) S100A10 in normal and OA
donors. Data are represented as relative gene expression compared to GAPDH. Histograms represent means 95%CI. *P < 0.05, ***P < 0.001. Data were evaluated using Student's t test
(normal n ¼ 8, OA n ¼ 3).
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formation of a heterotetramer (AIIt), interacting with plasminogen
activator and plasminogen, stimulating its activation47. Through
MAPK and NFkb, AIIt induces IL1b, IL6 and tumour necrosis factor
(TNF)a and consequently, silencing of S100A10 was demonstrated
to reduce the secretion of TNFa, IL1b and Il10 in lipopolysaccharide
stimulated chondrocytes48. Thus S100A10 has been proposed as a
target for OA therapeutics. In our study we identiﬁed an increase in
S100A10 protein in cartilage, but a reduction in the synovium in OA
using IHC. It is therefore probable that the increase in S100A10 in SF
evident in OA is due to an increase in its presence in cartilage, due
to cartilage pathology in OA. This is then ‘shed’ into the SF on
cartilage breakdown.
We also investigated OA-speciﬁc cleavage patterns in the ECM
by assessing fragmentation patterns of speciﬁc matrix molecules in
OA SF. A catalogue of ECM protein fragments, produced by frag-
mentation of the original peptide by enzymatic cleavage between
two amino acids, which we have termed ‘neopeptides’, were
identiﬁed in this study, and are likely due to speciﬁc proteinase
cleavage. In our previous studies in equine ageing and diseased
tendon we identiﬁed both tendinopathy and age-speciﬁc neo-
peptides22. In another study we identiﬁed age and OA related
neopeptides in equine cartilage13. In this study all donor ages were
similar and so we consider the neopeptides not to be age-speciﬁc. A
number of previously documented, as well as novel neopeptides
were identiﬁed here. These may represent proteolytic cleavage
occurring as a consequence of pathological degradation, or they
may be produced during sample processing as cell death can
release intracellular proteases. The latter is unlikely as SF was
collected rapidly post-mortem and immediately frozen. The neo-
peptides documented in this paper represent only those identiﬁed
in young OA SF and it would be interesting to undertake further
work on normal SF at different from donors of different ages in
order to assess neopeptides produced by normal cartilage ageing as
opposed to disease. A number of collagen-I and -VI neopeptides
were identiﬁed. It is possible that the collagen-I neopeptides are
from subchondral bone pathology which was evident in some
samples on histological examination. It has been demonstrated that
collagen VI gene expression is increased in OA and that it loses its
pericellular location49.
Conclusion
We demonstrated our novel workﬂow technique involving
peptide-based equalisation followed by liquid chromatographycoupled to a high mass resolution mass-spectrometer was appro-
priate for SF proteomics for both discovery and quantiﬁcation. We
discovered a distinct set of proteins that may act as potential bio-
markers to distinguish between normal and OA joints. Further
investigation postulated a role for S100A10 and CD109 in OA
pathogenesis. Finally we also identiﬁed a catalogue of neopeptides
in SF for the ﬁrst timewhich may increase our understanding of OA
pathogenesis and act as potential OA biomarkers.
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